WongE, RosenLS, MulayM, VanvugtA, DinolfoM, TomodaC, SugawaraM, HershmanJM. 2007. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 17:351–355.
2.
TorinoF, BarnabeiA, ParagliolaR, BaldelliR, AppetecchiaM, CorselloSM. 2013. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid, 23:1345–1366.
3.
RotiE, MinelliR, GardiniE, BianconiL, SalviM, GavaruzziG, UgolottiG, BravermanLE. 1994. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease. J Clin Endocrinol Metab, 78:795–799.
SalemAK, FentonMS, MarionKM, HershmanJM. 2008. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid, 18:631–635.
6.
KappersMH, van EschJH, SmedtsFM, de KrijgerRR, EechouteK, MathijssenRH, SleijferS, LeijtenF, DanserAH, van den MeirackerAH, VisserTJ. 2011. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab, 96:3087–3094.
7.
Makita N MiyakawaM, FujitaT, IiriT. 2010. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid, 20:323–326.